Astrazeneca wins fast-track approval for bladder cancer drug
17th Feb 2016 07:09
(ShareCast News) - AstraZeneca has won fast-track US regulatory approval for a particular application of its most promising cancer drugs. Durvalumab, a highly innovative immuno-oncology treatment that helps empower the patient's immune system and attack the cancer, has been given Breakthrough Therap
Read moreBroker tips: Wood Group, ITV, AstraZeneca
8th Feb 2016 15:55
(ShareCast News) - Wood Group shares fell after Goldman Sachs downgraded the company from 'neutral' to 'sell' and cut its target price from 639.6p to 517.6p. In a note on Monday, the investment bank focused on working capital analysis, which it believed would be the key there for the oil services se
Read moreMonday broker round-up
8th Feb 2016 15:02
(ShareCast News) - Petrofac: Goldman Sachs downgrades to neutral with a target of 909.8p. G4S: Jefferies downgrades to underperform with a target price of 170p. Cairn Energy: RBC keeps at outperform, 200p target. Wood Group: Goldman Sachs downgrades to sell, 517.6p target. Amec Foster Wheeler: No
Read moreHSBC downgrades AstraZeneca, sees no near-term relief
8th Feb 2016 12:18
(ShareCast News) - HSBC downgraded AstraZeneca to 'hold' from 'buy' and cut the price target to 4,880p from 4,910p. It said the company's full year results last Thursday were solid, slightly ahead of expectations in terms of sales and in line at core earnings per share level. The bank said declines
Read moreFriday broker round-up
5th Feb 2016 15:07
(ShareCast News) - Enterprise Inns: Barclays downgrades to underweight with a target of 80p. Thomas Cook: HSBC reiterates hold with a target price of 100p and JP Morgan keeps at overweight with a 170p target. Victrex: Deutsche Bank keeps at hold, 2000p target, UBS maintains neutral with a target
Read moreFriday newspaper share tips: AstraZeneca at least worth holding on to
5th Feb 2016 10:44
(ShareCast News) - AstraZeneca was in focus in Friday's newspaper share tips after it warned 2016 profits could be hit with the expiry of the patent on its anti-cholesterol drug Crestor. The FTSE 100 company said it sees a low to mid single-digit percentage decline in both sales and profits in 2016
Read moreThursday broker round-up
4th Feb 2016 16:07
(ShareCast News) - Coca-Cola HBC: Barclays downgrades to underweight with a target of 1325p. TalkTalk: Goldman Sachs downgrades to neutral with a target of 271p. Paragon Group: JP Morgan downgrades to neutral and sets a 380p target. Antofagasta: Investec reiterates sell with a target of 305p. Ang
Read moreFTSE 100 movers: Anglo surges as miners rise
4th Feb 2016 14:22
(ShareCast News) - The FTSE 100 had turned things around on Thursday, with the blue chip market in the green by mid-afternoon for the first time this week, up 33.66 points (0.58%) to 5,870.80. Miners were the biggest risers of the day as commodity prices rose as well as Asian stocks. Anglo American,
Read moreAstraZeneca warns of declining profits in 2016
4th Feb 2016 07:30
(ShareCast News) - Astrazeneca's shares dropped on Thursday after warning that the expiry of the patent on its anti-cholesterol drug Crestor will cut its profits this year on competition from cheaper generic versions. The FTSE 100 company said it sees a low to mid single-digit percentage decline
Read moreAstraZeneca wins EU approval for lung cancer drug Tagrisso
3rd Feb 2016 07:08
(ShareCast News) - AstraZeneca has won European regulatory approval to market its Tagrisso-branded tablets for the treatment of adult patients with certain forms of lung cancer. Tagrisso, which becomes the first new medicine to be approved under the European Commission's expedited process, will be a
Read moreAstraZeneca prostate cancer therapy reaches major milestone
28th Jan 2016 07:32
(ShareCast News) - One of AstraZeneca's cancer therapies reached a new milestone on Thursday, with the US Federal Drug Administration granting Lynparza a Breakthrough Therapy designation (BTD) for the treatment of a certain strain of prostate cancer. The FTSE 100 pharmaceutical firm said the Breakth
Read moreGSK, AstraZeneca and J&J join forces with universities for tech transfer fund
25th Jan 2016 15:21
(ShareCast News) - AstraZeneca, GlaxoSmithKline and Johnson & Johnson and three leading UK universities are joining forces to try to significantly improve the speed that academic scientific research is translated into new medicines. The University of Cambridge, Imperial College London and University
Read moreLondon close: Homebuilders lead bounce after Carney's remarks
19th Jan 2016 16:15
(ShareCast News) - Equities bounced back on Tuesday as a slowdown in Chinese economic growth fuelled stimulus hopes in Asia's largest economy and following 'dovish' remarks from the Governor of the Bank of England. The Footsie finished 96.88 points or 1.68% higher at 5,876.80 points, while the secon
Read moreBroker tips: AstraZeneca, BAE Systems, Unilever
19th Jan 2016 10:57
(ShareCast News) - Barclays upgraded AstraZeneca to 'equalweight' from 'underweight' and lifted the price target to 5,000p from 4,400p following a review of the pipeline and the recent Acerta Pharma and ZS Pharma deals. It said the upgrade reflected "an attractive growth outlook balanced by the pote
Read moreBarclays upgrades AstraZeneca on attractive growth outlook
19th Jan 2016 08:55
(ShareCast News) - Barclays upgraded AstraZeneca to 'equalweight' from 'underweight' and lifted the price target to 5,000p from 4,400p following a review of the pipeline and the recent Acerta Pharma and ZS Pharma deals. It said the upgrade reflected "an attractive growth outlook balanced by the pote
Read more